Immune Profiles and Circulating Tumor Cell Status Following Prostate Cryotherapy
NCT ID: NCT01454037
Last Updated: 2012-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
160 participants
OBSERVATIONAL
2011-10-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prostate cryoablation
Subjects receiving cryotherapy for prostate cancer
Prostate cryotherapy
cryoablate the prostate
Radical prostatectomy
Subjects receiving radical prostatectomy
Radical prostatectomy
Remove prostate
Radiation
Subjects receiving radiation for prostate cancer
Radiation
Radiate prostate
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prostate cryotherapy
cryoablate the prostate
Radical prostatectomy
Remove prostate
Radiation
Radiate prostate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histopathology-proven prostate adenocarcinoma
* Non-metastatic localized disease
* Subjects have chosen their curative, definitive treatments for prostate cancer prior to enrolling for the study
* Subjects are willing to sign the informed consent and agree to comply with the study procedures
Exclusion Criteria
* Concurrent use of immunosuppressive therapy, including: cyclosporine, antithymocyte globulin, or tacrolimus within 3 months of study entry
* Other conditions the investigators think may affect subjects' compliance
20 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Taiwan University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yeong-Shiau Pu, PhD
Role: PRINCIPAL_INVESTIGATOR
National Taiwan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Taiwan University Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Yeong-Shiau Pu, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201107059RB
Identifier Type: -
Identifier Source: org_study_id